The sunset clause is a rule governing the expiration of a marketing authorisation due to a lack of actual market presence. A marketing authorisation loses its validity if the medicinal product is not actually placed on the market within three years of being granted, or if a previously marketed product is no longer actually present on the market for three consecutive years. The rule links the continued existence of the authorisation to its actual placement on the market, rather than solely to its formal granting.
Purpose and Legal Trigger
The sunset clause prevents authorisations without market activity from persisting indefinitely. It applies to two scenarios: first, when an authorised medicinal product is not actually placed on the market after the authorisation is granted. Second, when a medicinal product was on the market but is no longer actually present there for a continuous period. In both cases, the law specifies a period of three years.
For centrally authorised medicinal products, the rule is contained in Article 14 of Regulation (EC) No 726/2004. Directive 2001/83/EC contains the corresponding provision for national authorisations. In exceptional circumstances and for reasons of public health, the competent authority may grant exemptions from the sunset clause. An exemption requires adequate justification; it is not the standard consequence of a merely delayed market launch.
The clause concerns the validity of the marketing authorisation. It does not address whether a product is commercially successful, whether it is reimbursed, or whether individual batches are available. The decisive factor is the actual presence of the authorised medicinal product on the market according to the relevant regulatory criteria. Companies must therefore maintain transparent documentation of authorisation status, supply capability, and the start of distribution.
Practical Monitoring in the Product Lifecycle
For authorisation holders, the sunset clause is a lifecycle obligation with interfaces to supply chain, quality, regulatory affairs, and pharmacovigilance. Following authorisation, it should be clearly documented when and where the medicinal product was actually placed on the market. In the event of supply interruptions, withdrawals, strategic market exits, or delayed launches, it must be checked whether the three-year period is affected and whether a justified exemption could be considered.
The rule is not limited to new medicinal products. Even a long-authorised product can lose its authorisation if, following previous marketing, it is no longer actually present on the market for three consecutive years. The sunset clause should therefore be monitored not only during the initial launch but continuously within portfolio management. Variations or a renewal of the authorisation do not automatically remedy a lack of market presence.
Distinction from Revocation, Renewal, and Suspension
The sunset clause is not a revocation for safety reasons. A revocation, suspension, or restriction due to an unfavorable benefit-risk balance is based on a regulatory safety or quality decision. In contrast, the sunset clause is triggered by a lack of market presence. It does not assess whether the medicinal product is effective or safe, but rather whether the authorisation was actually used within the legally defined period.
It must also be distinguished from the renewal of the authorisation. Renewal occurs after the initial five-year period of validity based on a re-evaluation of the benefit-risk balance. The sunset clause can take effect independently of this if the product is not placed on the market or leaves the market for three years. A suspension of the authorisation or a commercial distribution decision is therefore not automatically equivalent to a guaranteed maintenance of the authorisation.
Relevance for clinical trials
Clinical trials do not automatically lead to the market availability of a medicinal product. After authorisation, development, manufacturing, and distribution planning must be coordinated so that the transition to actual placement on the market remains regulatory traceable. Delays in manufacturing, labeling, the supply chain, or provision in intended markets can create lifecycle risks. For post-authorisation studies, it should also be clear whether the product remains on the market and how safety and application data will continue to be collected.
Full-service CROs like Mediconomics provide support in planning post-authorisation studies, pharmacovigilance, data management, medical writing, and regulatory documentation. They can align clinical and safety activities with lifecycle milestones, prepare data for ongoing benefit-risk assessment, and structure the collaboration between the study organization, authorisation holder, and regulatory affairs so that relevant information on product status and obligations is transparently available.
Frequently Asked Questions (FAQ)
When does an authorisation expire under the sunset clause?
When the medicinal product is not actually placed on the market within three years of authorisation, or is no longer present on the market for three consecutive years following earlier placement on the market.
Is the sunset clause a safety measure?
No. It is based on a lack of market presence, not on a regulatory re-evaluation due to a safety risk.
Can an exemption be granted?
Yes. In exceptional circumstances and for reasons of public health, justified exemptions may be provided.
Regulatory References
- Regulation (EC) No 726/2004, Article 14, paragraphs 4 to 6 — contains the sunset clause and exemptions in the centralized procedure.
- Directive 2001/83/EC, Article 24, paragraphs 4 to 6 — contains the corresponding regulation for national authorisations.
- EMA, Renewal and annual re-assessment — categorizes authorisation duration and lifecycle obligations.
